- Home
- PSTL vs DRUG Comparison
PSTL vs DRUG Comparison
Compare PSTL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- DRUG
- Stock Information
- Founded
- PSTL 2018
- DRUG 2019
- Country
- PSTL United States
- DRUG United States
- Employees
- PSTL N/A
- DRUG N/A
- Industry
- PSTL Real Estate Investment Trusts
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PSTL Real Estate
- DRUG Health Care
- Exchange
- PSTL Nasdaq
- DRUG Nasdaq
- Market Cap
- PSTL 329.8M
- DRUG 345.6M
- IPO Year
- PSTL 2019
- DRUG N/A
- Fundamental
- Price
- PSTL $14.96
- DRUG $51.50
- Analyst Decision
- PSTL Buy
- DRUG Strong Buy
- Analyst Count
- PSTL 2
- DRUG 9
- Target Price
- PSTL $17.38
- DRUG $81.67
- AVG Volume (30 Days)
- PSTL 165.7K
- DRUG 93.2K
- Earning Date
- PSTL 11-03-2025
- DRUG 08-11-2025
- Dividend Yield
- PSTL 6.47%
- DRUG N/A
- EPS Growth
- PSTL 344.13
- DRUG N/A
- EPS
- PSTL 0.39
- DRUG N/A
- Revenue
- PSTL $86,535,000.00
- DRUG N/A
- Revenue This Year
- PSTL $23.20
- DRUG N/A
- Revenue Next Year
- PSTL $10.24
- DRUG N/A
- P/E Ratio
- PSTL $38.72
- DRUG N/A
- Revenue Growth
- PSTL 26.43
- DRUG N/A
- 52 Week Low
- PSTL $12.26
- DRUG $0.94
- 52 Week High
- PSTL $16.50
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- PSTL 31.89
- DRUG 53.51
- Support Level
- PSTL $15.27
- DRUG $48.90
- Resistance Level
- PSTL $15.71
- DRUG $61.72
- Average True Range (ATR)
- PSTL 0.29
- DRUG 4.12
- MACD
- PSTL -0.14
- DRUG -0.22
- Stochastic Oscillator
- PSTL 0.65
- DRUG 41.50
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.